Susana Lozano-Esparza , Hugo Rodrigo Sánchez-Blas , Fidel David Huitzil-Meléndez , Mónica Isabel Meneses-Medina , Katherine Van Loon , Michael B. Potter , Alejandro Mohar , Martin Lajous
{"title":"墨西哥的结直肠癌存活率:利用全国医疗保险数据库。","authors":"Susana Lozano-Esparza , Hugo Rodrigo Sánchez-Blas , Fidel David Huitzil-Meléndez , Mónica Isabel Meneses-Medina , Katherine Van Loon , Michael B. Potter , Alejandro Mohar , Martin Lajous","doi":"10.1016/j.canep.2024.102698","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>We estimated the 5-year overall, age at diagnosis- and stage-specific colorectal cancer survival in patients treated through their coverage with <em>Seguro Popular</em>.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study using a dataset that included 1418 colorectal cancer patients covered by <em>Seguro Popular</em> (Mexico’s public health insurance system covering 60 % of the population) between 2013 and 2016. Deaths were identified using the Epidemiologic Death Statistics Subsystem registry, with a specialized algorithm for record linkage. The Kaplan-Meier method was used to estimate overall survival curves and the proportion of patients alive at various follow-up time points. We compared survival curves across subgroups using the log-rank test.</div></div><div><h3>Results</h3><div>In this study the average age at diagnosis was 56 years with 31.9 % of patients diagnosed before the age of 50. Most cases (78.1 %) were diagnosed in advanced stages (i.e., III and IV), with nearly half of the cases originating in the rectum. The overall 5-year survival was 50 %, with higher survival (74 %) for patients with stage I-II and lower survival for those with stage III (58 %) and IV (33 %). While age at diagnosis was not associated with survival for early-stage colorectal cancer, younger patients with metastatic disease had a worse prognosis compared to older patients.</div></div><div><h3>Conclusion</h3><div>The 5-year overall colorectal cancer survival was 50 %, with variation by clinical stage. Almost 80 % of the population was diagnosed with advanced stages, underscoring the need for screening programs. Younger patients with metastatic disease exhibited a worse prognosis, highlighting the need for targeted interventions.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102698"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Colorectal cancer survival in Mexico: Leveraging a national health insurance database\",\"authors\":\"Susana Lozano-Esparza , Hugo Rodrigo Sánchez-Blas , Fidel David Huitzil-Meléndez , Mónica Isabel Meneses-Medina , Katherine Van Loon , Michael B. Potter , Alejandro Mohar , Martin Lajous\",\"doi\":\"10.1016/j.canep.2024.102698\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>We estimated the 5-year overall, age at diagnosis- and stage-specific colorectal cancer survival in patients treated through their coverage with <em>Seguro Popular</em>.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study using a dataset that included 1418 colorectal cancer patients covered by <em>Seguro Popular</em> (Mexico’s public health insurance system covering 60 % of the population) between 2013 and 2016. Deaths were identified using the Epidemiologic Death Statistics Subsystem registry, with a specialized algorithm for record linkage. The Kaplan-Meier method was used to estimate overall survival curves and the proportion of patients alive at various follow-up time points. We compared survival curves across subgroups using the log-rank test.</div></div><div><h3>Results</h3><div>In this study the average age at diagnosis was 56 years with 31.9 % of patients diagnosed before the age of 50. Most cases (78.1 %) were diagnosed in advanced stages (i.e., III and IV), with nearly half of the cases originating in the rectum. The overall 5-year survival was 50 %, with higher survival (74 %) for patients with stage I-II and lower survival for those with stage III (58 %) and IV (33 %). While age at diagnosis was not associated with survival for early-stage colorectal cancer, younger patients with metastatic disease had a worse prognosis compared to older patients.</div></div><div><h3>Conclusion</h3><div>The 5-year overall colorectal cancer survival was 50 %, with variation by clinical stage. Almost 80 % of the population was diagnosed with advanced stages, underscoring the need for screening programs. Younger patients with metastatic disease exhibited a worse prognosis, highlighting the need for targeted interventions.</div></div>\",\"PeriodicalId\":56322,\"journal\":{\"name\":\"Cancer Epidemiology\",\"volume\":\"94 \",\"pages\":\"Article 102698\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Epidemiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877782124001772\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877782124001772","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:我们估算了通过参加 Seguro Popular 保险接受治疗的结直肠癌患者的 5 年总生存率、诊断年龄和分期生存率:我们使用一个数据集开展了一项回顾性研究,该数据集包括 2013 年至 2016 年期间由 Seguro Popular(墨西哥的公共医疗保险系统,覆盖 60% 的人口)承保的 1418 名结直肠癌患者。死亡病例通过流行病学死亡统计子系统登记处进行确认,并采用专门的算法进行记录链接。我们采用卡普兰-梅耶法估算了总体生存曲线和不同随访时间点的存活患者比例。我们使用对数秩检验比较了不同亚组的生存曲线:本研究中,确诊患者的平均年龄为 56 岁,其中 31.9% 的患者在 50 岁之前确诊。大多数病例(78.1%)被诊断为晚期(即 III 期和 IV 期),近一半的病例起源于直肠。总的 5 年存活率为 50%,其中 I-II 期患者的存活率较高(74%),而 III 期(58%)和 IV 期(33%)患者的存活率较低。虽然诊断时的年龄与早期结直肠癌患者的生存率无关,但与年龄较大的患者相比,患有转移性疾病的年轻患者预后较差:结论:结直肠癌患者的 5 年总生存率为 50%,不同临床阶段的生存率有所不同。近 80% 的患者被确诊为晚期,这凸显了筛查计划的必要性。患有转移性疾病的年轻患者预后较差,这说明有必要采取有针对性的干预措施。
Colorectal cancer survival in Mexico: Leveraging a national health insurance database
Purpose
We estimated the 5-year overall, age at diagnosis- and stage-specific colorectal cancer survival in patients treated through their coverage with Seguro Popular.
Methods
We conducted a retrospective study using a dataset that included 1418 colorectal cancer patients covered by Seguro Popular (Mexico’s public health insurance system covering 60 % of the population) between 2013 and 2016. Deaths were identified using the Epidemiologic Death Statistics Subsystem registry, with a specialized algorithm for record linkage. The Kaplan-Meier method was used to estimate overall survival curves and the proportion of patients alive at various follow-up time points. We compared survival curves across subgroups using the log-rank test.
Results
In this study the average age at diagnosis was 56 years with 31.9 % of patients diagnosed before the age of 50. Most cases (78.1 %) were diagnosed in advanced stages (i.e., III and IV), with nearly half of the cases originating in the rectum. The overall 5-year survival was 50 %, with higher survival (74 %) for patients with stage I-II and lower survival for those with stage III (58 %) and IV (33 %). While age at diagnosis was not associated with survival for early-stage colorectal cancer, younger patients with metastatic disease had a worse prognosis compared to older patients.
Conclusion
The 5-year overall colorectal cancer survival was 50 %, with variation by clinical stage. Almost 80 % of the population was diagnosed with advanced stages, underscoring the need for screening programs. Younger patients with metastatic disease exhibited a worse prognosis, highlighting the need for targeted interventions.
期刊介绍:
Cancer Epidemiology is dedicated to increasing understanding about cancer causes, prevention and control. The scope of the journal embraces all aspects of cancer epidemiology including:
• Descriptive epidemiology
• Studies of risk factors for disease initiation, development and prognosis
• Screening and early detection
• Prevention and control
• Methodological issues
The journal publishes original research articles (full length and short reports), systematic reviews and meta-analyses, editorials, commentaries and letters to the editor commenting on previously published research.